# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2024 Earnings Results

**Report date:** 2025-02-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2024

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.53%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $12.07 | N/A | +25.51% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Overall, management conveyed a positive outlook despite not providing specific guidance. They emphasized the strength of their product pipeline.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They expressed optimism about future growth opportunities.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Regeneron's strong EPS performance, exceeding expectations by over 25%, likely reflects effective cost management and robust sales in its product lines. The stock rose by 4.53% following the announcement, indicating investor confidence in the company's future prospects. However, the lack of revenue data and guidance leaves some uncertainty about the overall financial picture.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2024_